Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Slides:

Advertisements

Similar presentations

Cancer Genome Landscapes

Advertisements

Figure 1. Exploring and comparing context-dependent mutational profiles in various cancer types. (A) Mutational profiles of pan-cancer somatic mutations,

The cBio Cancer Genomics Portal.

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.

Landscape overview of GENIE dataset.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Focus on colon cancer Cancer Cell

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

by Jonathan Reichel, Amy Chadburn, Paul G

Volume 74, Issue 5, Pages (November 2018)

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Genomic alterations in breast cancer cell line MDA-MB-231.

Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer,

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Intrinsic and acquired trastuzumab resistance.

Abdul K. Siraj, Tariq Masoodi, Rong Bu, Shaham Beg, Saif S

Volume 29, Issue 5, Pages (May 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 25, Issue 5, Pages e5 (October 2018)

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Diverse abnormalities manifest in RNA

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Fig. 1. Genomic landscape of serial tumor biopsies and genomic and immune correlates of treatment response. Genomic landscape of serial tumor biopsies.

Genetic landscape of salivary duct carcinoma.

Bar plot representation of the transcriptomic changes in Δsaci_ptp and Δsaci_pp2a. Bar plot representation of the transcriptomic changes in Δsaci_ptp and.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC. Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC.

Cancer mutations in enriched RBP motifs.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

HER2 mutations identified by colorectal cancer genome sequencing studies increase cell signaling and anchorage-independent growth in a colonic epithelial.

Integrated mRNA and microRNA expression and DNA methylation clusters.

Heat map of genes for which CR significantly altered expression versus AL. Cluster analysis of genes significantly changed by the CR intervention compared.

Relationship between the expression of immune-related genes and burdens of somatic mutation. Relationship between the expression of immune-related genes.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Transcriptional and genomic targets of EN1 in TNBC cells.

Somatic mutational rates and survival analysis of IBD-CRC.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Targetable alterations and pathways in TNBCs after NAC

Temporal and spatial dissection of mutation spectra in esophageal adenocarcinoma samples. Temporal and spatial dissection of mutation spectra in esophageal.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

HGSOC mutational processes are established early and are patient-specific. HGSOC mutational processes are established early and are patient-specific. A,

Delineating cancer evolution with single-cell sequencing

The long tail of mutational hotspots in cancer.

Frequently mutated genes in colorectal cancer.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

Molecular definitions of lung adenocarcinoma subtypes.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Single nucleotide polymorphism array analysis can distinguish different genetic mechanisms that lead to loss of heterozygosity (LOH). Single nucleotide.

Strategies for personalized precision immunotherapy.

Germline variants influencing primary tumor type.

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Mutational load and mutations in the interferon signaling pathway among patients with advanced melanoma with or without response to anti–PD-1 blockade.

PTEN genotype frequently dictates PTEN expression status, but evidence of heterogeneous staining implies polyclonality within some ovarian tumors. PTEN.

The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Driver pathways and key genes in OSCC

Recurrent tumor cell–intrinsic transcriptomic, RTKinomic, and immune regulomic alterations in regressing melanoma on MAPKi therapy. Recurrent tumor cell–intrinsic.

Integrated analysis of gene expression and copy number alterations.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

Genomic instability is a core feature of ovarian cancer that frequently involves DNA-damage repair genes. Genomic instability is a core feature of ovarian.

Genomic and proteomic profiling of ovarian cancer cell lines.

Molecular characterization of esophagogastric tumors.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Transcriptome profiling of PD-L1 antibody–treated macrophages showed inflammatory phenotype, increased survival and proliferation, and decreased apoptosis.

Presentation transcript:

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for 71 samples displayed as columns, including somatic mutations, high-level amplifications and homozygous del... Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for 71 samples displayed as columns, including somatic mutations, high-level amplifications and homozygous deletions, and germline mutations for selected genes. For each sample, the site of biopsy, the ABSOLUTE neoplastic cellularity (purity) from WES data, and the neoplastic cellularity as assessed by histologic evaluation are shown as tracks at the top. Significantly mutated genes with q value ≤ 0.1 that were identified by exome sequencing are listed at the top (black) vertically in order of decreasing significance. Genes from recurrently altered functional classes are also shown, including tumor suppressor genes (yellow), oncogenes (red), DDR genes (green), and chromatin modification genes (blue). H&E, hematoxylin and eosin; LN, lymph node; Indel, insertion/deletion. Andrew J. Aguirre et al. Cancer Discov 2018;8:1096-1111 ©2018 by American Association for Cancer Research